The phase II trial, multicenter cohorts, open-label, single-arm study of VS-6063 treatment in heavily patients with KRAS mutant NSCLC indicated VS-6063 monotherapy demonstrated modest clinical activity [41]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.